X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/mgb-biopharma---successful-end-of-phase-2-meeting-with-fda-for-mgb-bp-3-a-potential-new-gold-standard-first-line-treatment-for-clostridioides-difficile-infection-cdi-301215669.html
https://www.prnewswire.com/news-releases/mgb-biopharma-announces-successful-outcome-from-phase-ii-clinical-study-with-mgb-bp-3--a-potential-new-gold-standard-first-line-treatment-for-clostridium-difficile-infection-cdi-301061497.html
https://www.prnewswire.com/news-releases/mgb-biopharma-announces-successful-outcome-from-phase-ii-clinical-study-with-mgb-bp-3--a-potential-new-gold-standard-first-line-treatment-for-clostridium-difficile-infection-cdi-301061497.html
http://www.pharmatimes.com/news/mgb_biopharma_reveals_positive_mid-stage_diarrhoea_data_1312794
https://www.fiercebiotech.com/biotech/mgb-tops-up-cash-pool-to-wrap-up-antibiotic-phase-2a
https://www.contractpharma.com/contents/view_breaking-news/2019-04-26/catalent-accelerates-formulation-and-supply-for-mgb-biopharma-candidate/
https://www.prnewswire.com/news-releases/mgb-biopharma-fda-and-health-canada-clear-ind-cta-applications-for-mgb-bp-3-a-novel-potent-bactericidal-antibiotic-targeting-clostridium-difficile-associated-diarrhoea-cdad--892224920.html
Market Place
Share 
